Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $3.3B; returns 1 day -5.4%, 1 week +0.2%, 1 year -0.2%.

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company whose revenue is overwhelmingly generated from the sale of its flagship product, XDEMVY® (lotilaner ophthalmic solution) 0.25%. This product is the first and only FDA-approved treatment for Demodex blepharitis, a common eyelid disease caused by Demodex mite infestation.

Groups TARS belongs to

• Biopharmaceutical
• Biotechnology
• Pharmaceuticals
• Healthcare
• Commercial Stage
• Commercial Stage Biotech
• Ophthalmology
• Unmet Medical Needs
• Life Sciences

TARS financial model: income statement, cash flow and balance sheet